IAEA Contribution to Nanosized Targeted Radiopharmaceuticals for Drug Delivery
Amir R. Jalilian,
Blanca Ocampo-García,
Wanvimol Pasanphan,
Tamer M. Sakr,
Laura Melendez-Alafort,
Mariano Grasselli,
Ademar B. Lugao,
Hassan Yousefnia,
Clelia Dispenza,
Siti Mohd Janib,
Irfan U. Khan,
Michał Maurin,
Piotr Ulański,
Say Chye Joachim Loo,
Agnes Safrany,
Joao A. Osso,
Adriano Duatti,
Kattesh V. Katti
Affiliations
Amir R. Jalilian
Department of Nuclear Sciences and Applications, International Atomic Energy Agency (IAEA), 1400 Vienna, Austria
Blanca Ocampo-García
Departamento de Materiales Radiactivos, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico
Wanvimol Pasanphan
Department of Materials Science, Faculty of Science, Kasetsart University, Bangkok 10900, Thailand
Tamer M. Sakr
Radioactive Isotopes and Generators Department, Hot Labs Center, Egyptian Atomic Energy Authority (EAEA), Cairo 13759, Egypt
Laura Melendez-Alafort
Istituto Oncologico Veneto IOV-IRCCS, Via Gattamelata 64, 35138 Padova, Italy
Mariano Grasselli
Laboratorio de Materiales Biotecnológicos (LaMaBio), Dpto de Ciencia y Tecnología, Universidad Nacional de Quilmes, Bernal 1876, Argentina
Ademar B. Lugao
Instituto de Pesquisas Energéticas e Nucleares, IPEN-CNEN, Av. Prof. Lineu Prestes, No. 2242, Cidade Universitária, São Paulo 05508-000, SP, Brazil
Hassan Yousefnia
Nuclear Science and Technology Research Institute (NSTRI), Tehran 11155-3486, Iran
Clelia Dispenza
Dipartimento di Ingegneria, Università deli Studi di Palermo, 90133 Palermo, Italy
Siti Mohd Janib
Medical Technology Division, Malaysian Nuclear Agency, Kajang 43000, Malaysia
Irfan U. Khan
Cyclotron and Allied Radiopharmaceutics Division, Institute of Nuclear Medicine and Oncology (INMOL), New Campus Road, Lahore 54600, Pakistan
Michał Maurin
National Centre for Nuclear Research, Radioisotope Centre POLATOM, 05-400 Otwock, Poland
Piotr Ulański
Institute of Applied Radiation Chemistry, Lodz University of Technology, 90-924 Łódź, Poland
Say Chye Joachim Loo
School of Materials Science & Engineering (MSE), Spore Centre of Environmental Life Sciences Engineering (SCELSE), Lee Kong Chian School of Medicine, Harvard T.H. Chan School of Public Health, Nanyang Technological University (NTU), Singapore 639798, Singapore
Agnes Safrany
Department of Nuclear Sciences and Applications, International Atomic Energy Agency (IAEA), 1400 Vienna, Austria
Joao A. Osso
Department of Nuclear Sciences and Applications, International Atomic Energy Agency (IAEA), 1400 Vienna, Austria
Adriano Duatti
Department of Chemical and Pharmaceutical Sciences, University of Ferrara, 44121 Ferrara, Italy
Kattesh V. Katti
Department of Radiology, Institute of Green Nanotechnology, School of Medicine, University of Missouri, University of Missouri Research Reactor (MURR), Medical School, One Hospital Drive, Columbia, MO 65212, USA
The rapidly growing interest in the application of nanoscience in the future design of radiopharmaceuticals and the development of nanosized radiopharmaceuticals in the late 2000′s, resulted in the creation of a Coordinated Research Project (CRP) by the International Atomic Energy Agency (IAEA) in 2014. This CRP entitled ‘Nanosized delivery systems for radiopharmaceuticals’ involved a team of expert scientist from various member states. This team of scientists worked on a number of cutting-edge areas of nanoscience with a focus on developing well-defined, highly effective and site-specific delivery systems of radiopharmaceuticals. Specifically, focus areas of various teams of scientists comprised of the development of nanoparticles (NPs) based on metals, polymers, and gels, and their conjugation/encapsulation or decoration with various tumor avid ligands such as peptides, folates, and small molecule phytochemicals. The research and development efforts also comprised of developing optimum radiolabeling methods of various nano vectors using diagnostic and therapeutic radionuclides including Tc-99m, Ga-68, Lu-177 and Au-198. Concerted efforts of teams of scientists within this CRP has resulted in the development of various protocols and guidelines on delivery systems of nanoradiopharmaceuticals, training of numerous graduate students/post-doctoral fellows and publications in peer reviewed journals while establishing numerous productive scientific networks in various participating member states. Some of the innovative nanoconstructs were chosen for further preclinical applications—all aimed at ultimate clinical translation for treating human cancer patients. This review article summarizes outcomes of this major international scientific endeavor.